).
D
epression is a common comorbid condition in patients with heart failure (HF) with prevalence rates reported to range from 13% to 77.5% depending on how depression is defined and assessed. 1, 2 Regardless of the prevalence figures used, depression in patients with HF has a much greater prevalence than that found in community settings, in which
The nature and direction of the relationship between HF and depression is not fully understood. The cause of depression is not clear, although it is believed that multiple factors are involved. Investigators have found that depression was independently associated with a substantial risk of HF among older persons with isolated systolic hypertension. 4 The association was not mediated by myocardial infarction. The investigators hypothesized that, since depressed persons show heightened activity of the sympathetic nervous system, this heightened sympathetic nervous system activity was involved in the pathogenesis of HF. Other studies of medically healthy adults have shown that depression is accompanied by higher levels of inflammatory markers for cardiac morbidity and mortality including interleukin-6, C-reactive protein, and tumor necrosis
Identifying and Treating Depression in Patients With Heart Failure The Problem of Inadequate Diagnosis and Treatment of Depression
Identification and effective treatment of comorbid depression is an essential component of high-quality clinical care of patients with HF. Unfortunately, fewer than 25% of cardiac patients with major depression are diagnosed as depressed, and only about one half of cardiac patients diagnosed as depressed receive treatment for depression. 6 Untreated depression has been reported to have an adverse impact on mortality rates, 7, 8 number and duration of perceived physical symptoms despite controlling for the severity of medical illness, 9 compliance with treatment recommendations, 10 functional ability, 2,3,9,11 family quality of life, 12, 13 use of medical resources and healthcare costs, 3, 14, 15 hospital admissions, 8, 16, 17 adverse drug reactions, 18 and physiologic mechanisms (ie, activation of the sympathetic nervous system, 5 decreased heart rate variability, 5 increased adhesiveness of platelets, 5, 19 elevated Creactive protein, 20 and maintenance of inflammatory processes once initiated 5 ). All of these adverse outcomes highlight the importance of identifying and treating depression.
Depression may be undiagnosed and untreated in patients with HF because (a) healthcare providers may be reluctant to ask; (b) patients may be hesitant to report depressive symptoms; (c) providers may mistakenly believe that depression is a normal reaction rather than a more serious treatable condition; and (d) many symptoms, such as fatigue, low energy, sleep disturbances, weight loss or gain, and concentration and memory problems, symptoms common to both depression and HF, may be diagnosed as symptomatic only of HF. 6 
Evaluating Patients for Clinical Depression
Assessment for depression in patients with HF is just as essential as assessment for other cardiovascular risk factors. Unless symptoms of depression are specifically looked for, they can be easily missed or mistaken for HF. 21 High-quality care for patients with HF and depression begins with recognition and accurate diagnosis. 22 Clinical depression is a syndromal diagnosis (ie, constellation of signs and symptoms) and there are no confirmatory or screening laboratory tests that are sufficiently sensitive or specific to help establish the diagnosis 23 rather the diagnosis is based on patient history and the exclusion of competing diagnoses. 22 There are several diagnostic categories of depression. Two of the diagnostic categories, major and minor depression, are especially important for patients with HF and are described in Table 1 . These categories of depression vary by the number of depressive symptoms present, which are described in Table 2 .
Case-finding and evaluating patients for depression when the clinical manifestation triggers the suspicion of depression are the 2 recommended approaches to recognizing and treating depression. 22 The first approach, case-finding, refers to asking patients with HF to complete a depression questionnaire during a routine appointment. Patients who score a specified threshold are evaluated more carefully for depression. There are several case-finding depression questionnaires, for example, Beck Depression Inventory, Center for Epidemiologic Studies Depression Scale, Geriatric Depression Inventory, Zung Self-Rating Depression Scale, and others that have been thoroughly described in the literature. 6, 25 Some experts have suggested a 2-question casefinding instrument for depression which assesses for depressed mood and anhedonia (absence of pleasure from acts that would normally cause pleasure). 26 If individuals answer "no" to these questions, clinical depression is unlikely. 22, 26 However, those answering "yes" to either of the 2 questions need to be asked additional questions to determine if there are sufficient symptoms to make a diagnosis of clinical depression. 22 The 2 questions are as follows: "During the past month, how often have you felt bothered by feeling down, depressed or hopeless?" and "During the past month, have you often been bothered by little interest or pleasure in doing things?" It is important to remember that culture can influence the experience and communication of symptoms of depression. 24 For example, complaints of "nerves" and headaches (in Latino and Mediterranean cultures), weakness, tiredness or "imbalance" (in Chinese and Asian cultures), and problems of the "heart" (in Middle Eastern cultures) may be used to describe the depressive experience. 24 The second approach is to evaluate HF patients for depression only when there is a suspicion of depression. This approach requires an understanding of the risk factors for depression in patients with HF. These risk factors include female gender, previous history of depression, family history of depression, prior suicide attempts, lack of social support, especially if living alone, unemployment or other stressful life events, current substance abuse, and loss of function or major life role. 6, 27, 28 It is important to remember that depression does correlate with indices of the functional severity of heart disease such as the New York Heart Association class, but not with physiological markers of heart disease severity such as leftventricular ejection fraction. 29 For either approach, a clinical interview is used to make a definitive diagnosis. Some experts recommend proceeding from open questions such as "How are things at home?" or "How are things at work?" to more narrowly focused questions that are guided by criteria from the Diagnostic and Statistical Manual of Mental Disorders. 24 Table 2 describes the Diagnostic and Statistical Manual of Mental Disorders (4th ed) diagnostic criteria of major depression and also gives examples of more narrowly focused assessment questions.
By using appropriate assessment questions, the provider can determine whether or not the patient fulfills criteria for depressive syndrome. Usually the depression will be associated with the patient's HF, but depression can be due to several other causes that should be ruled out. Physical conditions such as anemia, infection, hypothyroidism, or Cushing's disease may cause or mimic depression. 22 Because of the increased prevalence of hypothyroidism in women older than 50 years, some experts recommend a thyrotropin measurement. 22 Drugs may also cause a depressive syndrome and should be reviewed. Glucocorticoids, anabolic steroids, and cocaine or amphetamine withdrawal may cause depression. 22 Too much alcohol, use of illicit drugs, or abuse of prescription medicines can cause or complicate a major depressive episode and in most cases, if the substance is discontinued, the depression lifts. 30 Treating Depression in Patients With Heart Failure S49 At least 5 of the above symptoms must be present during the same 2-week period, nearly every day, and represent a change from previous functioning. At least one of the symptoms must either be (a) depressed mood or (b) loss of interest or pleasure.
Suicidal ideation is important to address. Given the increased prevalence of HF in the elderly, it is important to note that older Americans are disproportionately more likely to commit suicide. 31 Older white men are especially at risk; suicide is 6 times more common in elderly white men than in the general population. 32 Suicidal intent or behavior is often unrecognized by healthcare providers. Studies have found that among older adults who commit suicide, as many as 75% of them visited a primary care physician in the month before their suicide. 31 There is no evidence to suggest that asking about suicide gives people the idea to take their own life. 33 Useful questions to evaluate suicide risk include the following: "Have you ever thought about hurting yourself or taking your own life?" "If you were going to do that, what would you do?" "Sometimes when a person feels down or depressed, they might think about dying. Have you been having thoughts like that?" "How often do you think about it?" "Is it on a daily basis that you may think your life is not worth living and that you really do not know that you would be any worse off dead?" 22 For patients who report thinking about dying, it is important to follow up with questions about a suicide plan and determine if they have assembled any materials required, set a time, and if there may be factors that would either encourage or discourage them from carrying out the plan. 22 If it is determined that patients present a danger to themselves or others, treatment is urgent and the patient should remain in the medical setting for further evaluation.
Once the diagnosis of depression is established, there are a few other assessment questions to ask that will help guide treatment decisions. If the patient reports having had depressive episodes in the past, it is important to determine how the depression was treated. Antidepressant drugs that were used successfully in the past are likely to be tolerated and effective for the current episode. 22 It is also important to assess the number of prior depressive episodes since the risk of relapse, and therefore the need for longer term treatment, increases with the number of prior episodes.
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Treatment of Depression
Treatment is indicated if patients are diagnosed with either major or minor depression. If left untreated, depression imposes a significant psychosocial burden, impedes rehabilitation and recovery, and the depression itself may become chronic. 34 The aim of acute phase treatment is symptom remission. 30 Approaches to treatment of depression in HF include general measures, psychotherapy (cognitive-behavioral therapy [CBT]), pharmacotherapy, and, in certain instances, electroconvulsive therapy (ECT). Although there are no large prospective trials that have examined interventions aimed at decreasing depression in HF, there is evidence that nonpharmacologic and pharmacologic intervention may be effective and beneficial. Consulting or referring to a mental health specialist may be necessary in the following situations: (a) patient is actively suicidal, (b) psychosis is present, (c) specialized therapy such as electroconvulsive or light therapy are a consideration, (d) the patient fails to respond to 1 or 2 medication trials, (e) the patient's symptoms suggest a complex psychiatric diagnosis; (f) the patient wishes a second opinion, or (g) for some reason general guidelines cannot be followed or are not suitable for an individual patient. 30 The following paragraphs will discuss the major treatment approaches for depressed patients with HF.
General Measures
Optimization of Medical Therapy
Symptoms of HF are more likely to be reduced with adequate doses of ACE inhibitors, beta-blockers, diuretics, and digoxin as recommended by current treatment guidelines. 35 Although some practitioners may be reluctant to prescribe beta-blockers because of concerns about the development of common symptoms such as depression, fatigue, and sexual dysfunction, these concerns are not supported by data from clinical trials. According to randomized trial data, there is no significant increase in risk of depressive symptoms, and only small increased risks of fatigue and sexual dysfunction. 36 Depending on the severity of HF, other drugs such as spironolactone, eplerenone, intermittent use of an infusion of a positive inotropic drug, or nesiritide (Natrecor) may be needed to improve symptoms. 35, 37 Improvement in HF symptoms is likely to make an individual feel better and lead to a better quality of life, which may positively impact the patient's depression.
Patient Education
The general public often does not understand the illness of depression and may hold stigmatizing beliefs about it. Because of the stigmatization and general lack of knowledge about depression, patients may be resistant to the diagnosis and treatment of depression, underestimate its severity, or view depression as an expected response to HF. 22, 38 It is important that patients and their families understand that depression is a medical illness that is not their fault, that it did not happen because of a weakness of theirs, and that it is treatable. Let patients and their families know that treatment reduces the pain and suffering of depression, removes all of the symptoms of depression, and will return them to a better quality of life. 28 Other information to convey to patients is (a) that most people who are treated for depression feel better in several weeks; (b) because it takes several weeks for treatment to work fully, it is important to get treatment early before the depression gets worse; and (c) as with any medical condition, they may have to try 1 or 2 treatments before finding the best one.
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Exercise
Exercise should not be considered the only treatment for depression in HF but an additional treatment component. Benefits of physical activity include improvement in exercise tolerance and functional capacity and improvement in psychological wellbeing. [39] [40] [41] Physical activity should be encouraged, except during periods of acute decompensation or in patients with suspected myocarditis, because restriction of activity promotes physical deconditioning, which may adversely affect clinical status. 35 Rehabilitative exercise training in patients with HF improves not only functional capacity but also symptoms, both associated with the occurrence of depression in patients with HF. 42 Meta-analysis data indicate that exercise has an antidepressant effect and that it is a better antidepressant than are relaxation and enjoyable activities. 43 A meta-analysis of 13 to 15 studies on psychological effects of exercise programs in coronary patients found that there was a positive effect size for depression. 44 However the effect was determined to be less than the effect of psychotherapeutic interventions. Kostis et al 45 compared the effects of a nonpharmacologic intervention to those of digoxin and placebo in patients with HF. The nonpharmacologic treatment program included the following: graduated exercise training 3 to 5 times a week, dietary intervention, and structured cognitive therapy and stress management. At 12 weeks follow-up, in comparison with the digoxin and placebo groups, only the nonpharmacologic group experienced a significant improvement in depression. In summary, exercise is an important adjunct to treatment of depression in patients with HF.
Social Support
Social support is emerging as an important factor to consider among depressed patients with HF. Lack of support not only is an independent predictor of rehospitalizations and the occurrence of fatal and nonfatal cardiovascular events in the year after an HF admission, 46 ,47 but also negatively impacts depression. [48] [49] [50] In a study 51 of 107 patients with HF, among those patients who were depressed, social support predicted faster remission from depression. For each point increase on the social support index, the speed of remission increased by 16%. Conflicting relationships with friends and spouse warmth have been found to significantly impact recovery from depression in a community sample of depressed patients. 52 Conflicting relationships with friends was associated with less rapid recovery from depression. Patients who reported feeling warmth and compassion from their spouses were much more likely to recover in a given time period than those patients who did not report feeling spouse warmth and compassion. Using a sample of 183 patients with chronic cardiac illness, Holahan et al 53 found coping was a mechanism through which social support and social stressors related to subsequent depressive symptoms 4 years later. Positive aspects of relationships were related to more adaptive coping efforts, which were associated with fewer depressive symptoms. In summary, the social context of the depressed patient with HF is important and needs to be assessed. Patients with low levels of support may need assistance in problem solving about ways to enhance the availability of support in order to enhance full remission of depressive symptoms.
Family
Although the depressed patient is of primary concern, it is important to keep in mind that the patient is part of a family who is affected by the HF experience and related depression. Investigators have reported that although patients with HF are significantly more depressed than spouses, spouses also experience depression, 54, 55 and the risk for a spouse developing a depressive disorder increases when caring for a depressed patient. 56 Caregivers of chronically ill patients, primarily those experiencing chronic stress, commonly report symptoms of depression. 57 The number of caregiving tasks as well as activity restriction among spousal caregivers has been implicated as mediators of changes in depressive symptoms. 58 Family caregiving relative to patients with cardiovascular disease has been reported to be exhausting, 59 stressful, 59 ,60 and even fatal. 61 One study found that death rates were significantly higher among elderly spouses experiencing caregiver strain while caring for debilitated cardiac patients. 61 Witnessing negative personality changes 62 and experiencing social isolation 58 contribute to spouse burden and potentially to spouse depression.
The need to assess the family caregiver for depression and early intervention is an essential component of high-quality care for both the caregivers' psychological well-being and better patient outcomes. Combined high levels of stress and depression among caregivers have been reported to increase the risk of hospital readmission among patients with HF. 63 Clearly, more research is needed to investigate depression in this caregiver population. Since family support can positively impact the patient's depression, [48] [49] [50] [51] providing care to families should not be overlooked.
Family care can take the form of improving the family caregiving experience. 64 Keeping the family informed about the patient's HF and depression is important. Family caregivers reported higher scores in mental health, vitality, and perceived health when they received additional teaching and support from nurses. 65 Being sensitive to family needs and concerns; including family in discussions about care management and valuing their contributions; validating family members' emotional responses and helping them understand that those responses are normal; discussing with families ways to reduce their isolation; referring families to an appropriate support group; helping families open channels of communication; and helping families identify and mobilize their strengths and resources 66 are all ways to provide family care, which may indirectly lead to an improvement in the patient's depression.
Psychotherapy
Many psychosocial interventions have been tested for their effects on depression; however, psychotherapy is the nonpharmacological treatment with the greatest amount of empirical support and is recommended in treatment guidelines for depression. 30 A significant number (50%) of patients with mild to moderate forms of depression get relief from symptoms with psychotherapy. 30 Many patients begin to feel the effects of psychotherapy within the first few weeks. However, if there is no improvement in symptoms within 6 weeks, the choice of treatment should be reevaluated. 30 After 12 weeks, if patients are still symptomatic, treatment with medication should be given strong consideration. 30 Although there are many types of psychotherapy, CBT is particularly appropriate for patients with HF and will be described further below. Studies have confirmed the efficacy of CBT for treatment of depression. 
Cognitive-Behavioral Therapy
Cognitive-behavioral therapy may be considered if any of the following conditions is present: (a) depression is not severe, (b) depression is not chronic, (c) psychotic features are absent, (d) a previous response to CBT was positive, (e) CBT services are available, (f) a medical contraindication to medications exists, (g) recovery has not been achieved with medication alone, and/or (h) complicated psychosocial circumstances exist.
6 Table 3 provides general definitions of the levels of severity of depression that may help determine appropriate treatment.
Cognitive-behavioral therapy emphasizes selfcontrol over thinking pattern. This therapy proposes that dysfunctional thinking is common to all psychological disturbances and that people's feelings and behaviors are influenced by their perceptions and events. 68 A situation in and of itself does not determine what persons feel, but the way in which they construe the situation determines their feelings. 68 The goal of CBT is to train patients to change their interpretations of distressing situations and to seek new and different meanings for them. 68 For example, patients may believe that exercise may worsen their HF. As a result, activity may be restricted contributing to worse functional status and ongoing depression. Advanced practice nurses trained to conduct CBT can assess patients for irrational thoughts and then assist them to confront these thoughts by providing accurate information as to their true functional abilities. 
Pharmacotherapy
Treatment of depression with medications should be considered if any of the following conditions exists: (a) depression is severe, (b) depression is chronic or recurrent, (c) psychotic features are present, (d) there has been a previous positive response to medication, (e) there is a family history of depression, and (f) the patient is unable to do the required work of CBT. 6 There are 5 clinically relevant factors to be considered when selecting any drug for the depressed patient with HF: safety, tolerability, efficacy, payment, and simplicity. 69 Table 4 describes each of these factors. Individualization in the choice of specific agents is especially important in patients with 
Level of Depression Severity Definition
Severe depression An individual has nearly all of the symptoms of depression, and the depression almost always keeps them from doing their regular day-to-day activities Moderate depression An individual has many symptoms of depression that often keep them from doing things they need to do Mild depression An individual has some of the symptoms of depression, and it takes extra effort to do the things they need to do *Adapted from Depression Guideline Panel.
HF. Attention to the levels of cardiac function, electrocardiographic configuration, age, severity of the depression, as well as drug interactions all must be considered. It has been reported that patients with HF are taking an average of 6.6 Ϯ 1.2 drugs. 70 Issues related to polypharmacy must also be kept in mind. Determining serum levels of antidepressants is encouraged, especially in the elderly, to monitor renal and hepatic clearance.
Categories of antidepressant drugs include selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and miscellaneous antidepressants. All drugs available have similar efficacy and about 65% of patients experience a favorable response to the first drug prescribed. 38 The following paragraphs are by no means a complete index to antidepressant drug therapy in patients with HF, but rather a general guide to the most commonly used agents. To minimize overdose, it is recommended that the total dosage of any antidepressant medication be limited to 1 g or less per single prescription.
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Selective Serotonin Reuptake Inhibitors
Available evidence supports the effectiveness and favorable adverse effect profile of prescribing SSRIs for treatment and control of depression in patients with cardiovascular disease. 72 However, the estimated frequency of cardiovascular effects with SSRIs is less than 0.0003% 73 and there are a few published trials that have evaluated the use of SSRIs in patients with cardiac disease.
Unlike the tricyclic antidepressants, the SSRIs do not have significant hypotensive or proarrhythmic effects and have negligible effects on cardiac conduction, heart rate, and ECG intervals. 74, 75 Of note in particular is that SSRIs do not prolong the PR, QRS, or QT intervals. Multiple studies of SSRIs show no effect on heart rate variability or QT variability. 74 Furthermore the Sertraline Antidepressant Heart Randomized Trial, a randomized trial comparing an SSRI (sertraline) with a placebo in 369 patients with major depressive disorder and either acute myocardial infarction or unstable angina, found no statistically significant difference in left-ventricular ejection fraction between the groups. 73 Finally, the use of SSRIs is associated with beneficial anticoagulant effects, that is, reduction of platelet and endothelial activation. 76 Because of increased hemostasis and more thromboembolic events in patients with HF, the practitioner may wish to consider these actions, which are above and beyond the actions of aspirin, clopidogrel, and other anticoagulants. A recent review of the safety of antidepressant drugs in patients with cardiac disease recommended that patients with HF receive fluoxetine or sertraline. 73 Of these 2 drugs, sertraline may be the preferred agent because of its lack of effect on ventricular ejection fraction. 73 However, fluoxetine and other SSRIs can inhibit some of the cytochrome P450 isoenzymes, a series of hepatic isoenzymes involved in oxidative metabolism of several drugs. Selective serotonin reuptake inhibitors have the potential to interact with many drugs used to treat cardiac disease such as lipophilic beta-blockers (eg, metoprolol and propranolol), calcium channel blockers, type IC antiarrhythmics, angiotensin-converting enzyme inhibitors, anticonvulsants, antihistamines, benzodiazepines, TCAs, codeine, and warfarin. 34 Thus, although side effect profiles for tricyclic antidepressants are more problematic, SSRIs may have more risk associated with those on multiple medications due to the possibility of drug interactions. 75, 77 Advanced practices nurses should exercise caution when giving SSRIs to patients taking multiple drugs.
Tricyclic Antidepressants
Tricyclic antidepressants are the oldest agents available and have perhaps the most side effects. 73 Studies of safety and efficacy to date are limited in scope because of the short duration of most studies and the Treating Depression in Patients With Heart Failure S53 74 Anticholinergic effects may slow transit time sufficiently to reduce absorption of subsequent doses. Tricyclic antidepressants should be avoided in patients with glaucoma and benign prostatic hypertrophy since the anticholinergic effects exacerbate glaucoma and urinary retention. Multiple side effects and danger of overdose make tricyclic antidepressants difficult to use in the elderly. 38 Advanced practice nurses also need to be alert to clinically relevant drug interactions of tricyclic antidepressants with warfarin, aspirin, fluoxetine, and clonidine. 75 Additionally, these drugs can induce orthostatic hypotension, which can result in falls and serious injuries. 73, 74 Although tricyclic antidepressants do not routinely have an adverse effect on ventricular function in patients with left-ventricular impairment, they do increase heart rate by about 11% and slow AV conduction which can result in second-degree AV block in patients with preexisting bundle branch block. 74 Tricyclic antidepressants have a significant antiarrhythmic effect in much the same manner as Type 1A (Quinidine-like) antiarrhythmics and consequently can increase QT intervals. 75 They should be avoided in patients with preexistent long QTs or who are taking other QT interval-prolonging drugs such as quinidine, flecainide, erythromycin, loratadine, fexofenadine, or cetirizine. 75 Investigators from multiple studies have reported that tricyclic antidepressants decrease all component measures of heart rate variability and increase QT variability. 74 Despite being Type 1 antiarrhythmics, results from the cardiac arrhythmia suppression trials revealed that these drugs carry increased risk of mortality when given to patients with ischemic heart disease. 74 Tricyclic antidepressants are contraindicated in patients with ischemic disease and should be used cautiously, if at all in patients with a history of significant heart disease. 75 
Miscellaneous Antidepressants
Bupropion is an antidepressant drug that is neither a tricyclic antidepressant nor an SSRI. Its mechanism of action as an antidepressant is not known and has not been studied extensively in patients with cardiac disease. 73 Available data suggest that bupropion may increase blood pressure, so care must be taken in patients who have preexisting hypertension. 73 Trazodone is another miscellaneous antidepressant that has not been studied sufficiently in patients with cardiac disease. Existing data suggest trazodone has a sedative effect and lacks significant cardiovascular effects, although anecdotal evidence suggests the drug may increase PVCs. 73 Further studies are needed to evaluate the effects of these miscellaneous antidepressants in patients with HF.
Electroconvulsive Therapy
Electroconvulsive therapy is used when depression is severe, intractable, or life threatening, thus requiring immediate relief. 78 Relatively little data are available evaluating the efficacy and safety of ECT in HF; thus, we do not know the absolute or relative risk of ECT in these patients. The pathophysiological effects during and after administration of ECT include a brief period of bradycardia and hypotension followed by a brief period of sinus tachycardia and elevation of blood pressure. 78 ,79 Dysrhythmia appears to be the primary concern of ECT, 79 and at least one episode of asystole has been reported. 80 Although more research is necessary, it appears that increased risk is related to associated valvular disease or poorly controlled HF. 79 If ECT is being considered as a treatment for a patient with HF, it is important for the ECT team to be fully aware of the extent of the HF so that the necessary medically supportive treatment can be provided during the procedure.
Summary
Depression is a prominent comorbid condition in HF, which often goes undiagnosed and untreated. Assessment for depression in patients with HF is essential since it is a predictor of functional decline and death. Although more studies are needed, both nonpharmacological and pharmacological treatment approaches have been found to effectively treat depressed patients with HF.
